O W Akkerman
Overview
Explore the profile of O W Akkerman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
316
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cevik M, Sturdy A, Maraolo A, Dekkers B, Akkerman O, Gillespie S, et al.
Int J Tuberc Lung Dis
. 2024 Aug;
28(9):454-460.
PMID: 39188008
<sec><title>OBJECTIVES</title>The coexistence of TB and diabetes mellitus (DM) (TB-DM) is associated with an increased risk of treatment failure, death, delayed culture conversion, and drug resistance. Because plasma concentrations may influence...
2.
Longman K, Akkerman O, Ghimire S, Bolhuis M, Chambers M, Sturkenboom M, et al.
Int J Antimicrob Agents
. 2024 Jun;
64(2):107231.
PMID: 38918168
Background: Insufficient exposure and poor compliance with anti-tuberculosis (TB) medications are risk factors for treatment failure and the development of drug resistance. Measurement of drugs in biological samples, such as...
3.
Pontali E, Akkerman O, Zenner D, Migliori G
Int J Tuberc Lung Dis
. 2024 Mar;
28(3):113-114.
PMID: 38454189
No abstract available.
4.
Lever S, Akkerman O, Dekkers B
Int J Tuberc Lung Dis
. 2024 Mar;
28(3):163-165.
PMID: 38454182
No abstract available.
5.
Akkerman O, Kerstjens H, Kingma M, Bolhuis M, Sturkenboom M
Int J Tuberc Lung Dis
. 2024 Mar;
28(3):169-170.
PMID: 38454176
No abstract available.
6.
Akkerman O, Dijkwel R, Kerstjens H, van der Werf T, Srivastava S, Sturkenboom M, et al.
Int J Tuberc Lung Dis
. 2023 Sep;
27(10):772-777.
PMID: 37749836
Observational real-world studies on therapeutic drug monitoring (TDM) in relation to pharmacokinetic (PK) target values are lacking. This study aims to describe the PK of rifampicin (RIF) and isoniazid (INH)...
7.
Singh K, Carvalho A, Centis R, D Ambrosio L, Migliori G, Mpagama S, et al.
Int J Tuberc Lung Dis
. 2023 Jun;
27(7):506-519.
PMID: 37353868
Adverse effects (AE) to TB treatment cause morbidity, mortality and treatment interruption. The aim of these clinical standards is to encourage best practise for the diagnosis and management of AE....
8.
Bolhuis M, Akkerman O, Sturkenboom M, van Boven J, Alffenaar J, Stevens J
Int J Tuberc Lung Dis
. 2023 Apr;
27(4):335-337.
PMID: 37035978
No abstract available.
9.
Akkerman O, van Het Hof S, de Vries G, van Crevel R
Int J Tuberc Lung Dis
. 2023 Mar;
27(3):237-239.
PMID: 36855036
No abstract available.
10.
de Reus Y, Hagedoorn P, Sturkenboom M, Grasmeijer F, Bolhuis M, Sibum I, et al.
PLoS One
. 2022 Aug;
17(8):e0272034.
PMID: 35930536
Rationale: Inhaled antimicrobials enable high local concentrations where needed and, compared to orally administration, greatly reduce the potential for systemic side effects. In SARS-CoV-2 infections, hydroxychloroquine sulphate (HCQ) administered as...